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ABSTRAK 
 
Pengenalan:  
Pterigium adalah satu penyakit mata yang biasa di Malaysia kerana lokasi negara ini terletak 
berhampiran dengan khatulistiwa. Kajian terkini telah mendapati bahawa factor pertumbuhan 
endothelial vascular (VEGF) hadir dalam jumlah yang besar dalam epitelium pterigium 
terutama di kepalanya berbanding konjunktiva normal yang menunjukkan VEGF terlibat 
dalam angiogenesis dan pertumbuhan proliferatif fibrovaskular pterigium. Oleh itu, anti-
VEGF telah dicadangkan sebagai ubat tambahan tanpa label untuk pembedahan pterigium. 
 
Objektif:  
Untuk menilai kevaskularan dan saiz pterigium utama selepas suntikan ranibizumab intralesi 
dan kadar perulangan selepas pembedahan pterigium tanpa jahitan. 
 
Metodologi:  
Pesakit yang memerlukan pembedahan eksisi pterigium primer yang memenuhi kriteria 
kemasukan dan pengecualian dikenal pasti. Mereka kemudian secara rawak dimasukkan ke 
dalam kumpulan rawatan dan kawalan. Kumpulan rawatan disuntik dengan ranibizumab 
intralesi (0.3 mg/0.03 mL) 1 minggu sebelum pembedahan. Gambar segmen depan diambil 
sebelum dan 1 minggu selepas suntikan. Perubahan dalam kevaskularan pterigium (peratusan 
kawasan pterigium dilindungi oleh saluran darah) dan saiz (peratusan kawasan kornea 
dilindungi oleh pterigium) diukur menggunakan perisian analisis imej, Imej J. Satu minggu 
selepas suntikan ranibizumab, kedua-dua kumpulan rawatan dan kawalan menjalani 
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pembedahan eksisi pterigium dan lekatan autograf konjunktiva dengan gam fibrin. Rawatan 
susulan telah dibuat kepada pesakit selama 1 tahun bagi memantau perulangan dan 
komplikasi. 
 
Keputusan:  
36 pesakit (18 setiap kumpulan) telah selesai menjalani kajian. Min perubahan dalam 
kevaskularan pterigium adalah 1.48 (4.65)% manakala saiz pterigium adalah 0.28 (2.71)%. 
Kedua-dua pengurangan adalah tidak signifikan secara statistic (masing-masing p = 0.195 
dan 0.672). Kadar perulangan dalam kumpulan rawatan adalah 22.2% (n = 4) manakala 
kumpulan kawalan adalah 16.7% (n = 3). Kadar perulangan antara kumpulan tidak signifikan 
secara statistik (p > 0.950). 
 
Kesimpulan:  
Satu suntikan intralesi ranibizumab (0.3 mg/0.03 mL) tidak mengurangkan kevaskularan 
pterigium dan saiz secara ketara dalam masa 1 minggu. Suntikan ranibizumab intralesi pra-
pembedahan tidak mengurangkan kadar perulangan pterigium. 
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ABSTRACT 
 
Introduction: 
Pterygium is a common eye disorder in Malaysia due to the country’s location near to the 
equator. Recent study has found that vascular endothelial growth factor (VEGF) is present in 
great amount in pterygium epithelium especially in its head compared to normal conjunctiva 
suggesting that VEGF is involved in the angiogenesis and proliferative fibrovascular growth 
of pterygium. Thus, anti-VEGF has been proposed as an off-label adjunct to pterygium 
surgery. 
 
Objective: 
To evaluate the vascularity and size of primary pterygium after intralesional ranibizumab 
injection and the recurrence rate following sutureless pterygium surgery. 
 
Methodology: 
Patients presenting for primary pterygium excision who fulfilled our inclusion and exclusion 
criteria were identified. They were then randomised into treatment and control groups. 
Treatment group was injected with intralesional ranibizumab (0.3 mg/0.03 mL) 1 week prior 
to surgery. Anterior segment photographs were taken before and 1 week after the injection. 
Changes in pterygium vascularity (percentage of pterygium area covered by vessels) and size 
(percentage of cornea area covered by pterygium) were measured using image analysis 
software, Image J. 1 week after ranibizumab injection, both treatment and control groups 
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underwent pterygium excision and conjunctiva autograft adhesion with fibrin glue. Patients 
were followed-up for 1 year to monitor for recurrence and complication. 
 
Results: 
36 patients (18 each group) completed the study. Mean change in pterygium vascularity was  
1.48 (4.65)% while pterygium size was 0.28 (2.71) %. Both reductions were not statistically 
significant (p = 0.195 and 0.672 respectively). Recurrence rate in treatment group was 22.2% 
(n = 4) while controlled group was 16.7% (n = 3). Recurrence rate between groups was not 
statistically significant (p > 0.950). 
 
Conclusion: 
Single intralesional injection of ranibizumab (0.3 mg/0.03 mL) did not reduce the pterygium 
vascularity and size significantly in 1 week time. Pre-operative intralesional ranibizumab did 
not reduce pterygium recurrence rate. 
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1 INTRODUCTION 
 
1.1 Background 
Pterygium appears as a wing-like triangular (with apex towards the corneal centre) 
fibrovascular growth from bulbar conjunctival over the limbus onto the cornea. 
Histologically, pterygium is characterised by collagen fibres elostatic degeneration of the 
conjunctival stroma. The effect of pterygium can range from cosmetic, astigmatism to 
blinding if visual axis is encroached but mostly it is asymptomatic.  
 
1.2 Epidemiology of pterygium 
Pterygium is a common eye disorder in Malaysia due to the country’s location near to the 
equator. Prevalence is as high as 22% in equatorial areas compared to 2% in latitudes above 
40° (Dake et al., 1989). Prevalence of pterygium increases in dry, windy environment and 
increasing age (Goldberg and David, I976). However, recurrence is more frequent in young 
adults than older individuals (Lewallen, 1989). 
 
1.3 Pathogenesis of pterygium 
Pterygium was previously thought to be a degenerative condition.
 
However recent evidence 
suggests that pterygium is in fact a proliferative condition that is strongly correlated with 
exposure to ultraviolet radiation (UVR) (Hill and Maske, 1989).  
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Recent study found that vascular endothelial growth factor (VEGF) is present in great amount 
in pterygium epithelium especially in its head compared to normal conjunctiva by studies 
employing immunohistochemistry, suggesting that VEGF plays an important role in 
pterygium development.(Lee et al., 2001).
 
Thus, it is postulated that VEGF is involved in 
angiogenesis and it is produced by corneal fibroblasts in response to local conjunctival 
inflammation or other noxious stimulus caused by environmental UVR, dryness and dust 
(Blaudschun et al., 2002). 
 
To investigate further the association between VEGF and pterygium formation, Poenaru Sava 
et al. (2014) found that VEGF gene 460C polymorphism is associated with pterygium 
formation in female patients. Females who carried the allele which the gene is contained have 
increased risk of developing pterygium at a younger age.  
 
UVR affects the expression of various cytokines, and growth factors other than VEGF such 
as basic fibroblast growth factor (bFGF), transforming growth factor-beta (TGF-β), platelet-
derived growth factor (PDGF) and suppressed level of pigment epithelium-derived factor 
(PEDF) which also play a role in pterygium formation (Di Girolamo et al., 2004; Kria et al., 
1996). 
 
Other proposed pathogenesis are expression of P53 oncogene, viral infection, immunological, 
environmental, genetic and hereditary factors (Cilova-Atanasova, 1971; Hill and Maske, 
1989; Pinkerton et al., 1984; Solomon, 1985; Tan et al., 1997b; Tsironi et al., 2002). 
3 
 
1.4 Surgical treatment of pterygium 
The definitive treatment is by surgical removal of the lesion. The first reported surgical 
treatment of pterygium was more than 3000 years ago.
 
Since then, many variant of this 
procedure have been published. The most common operative technique at present is 
conjunctival autograft closure due to its low recurrence of 2.6%-39% (Lewallen, 1989). The 
transplantation of limbal stem cells from the graft helps regenerate new corneal epithelial 
cells in addition to inhibiting conjunctival epithelial invasion of the cornea (Tseng, 1989). 
 
The use of fibrin adhesive glue to secure the conjunctival autograft further reduces the 
recurrence rate, surgical time, and postoperative pain when compared with sutures 
(Ratnalingam et al., 2010). 
 
1.5 Adjunct to surgical treatment of pterygium 
The current treatment of pterygium focuses on prevention of its recurrence (Lekhanont et al., 
2012). The main concern for pterygium treatment is the recurrence which can be aggressive 
with more exuberant fibrovascular growth response (Lekhanont et al., 2012). Many 
adjunctive modalities have been introduced to prevent recurrence. These include beta 
irradiation and cytotoxic ankylating agent such as thiotepa and mitomycin C. However, none 
comes without serious complications and thus not used routinely nowadays (Hosseini et al., 
2007). 
 
Based on the high expression of VEGF in pterygium tissue and its role in pterygium 
angiogenesis, anti-VEGF has been proposed as an adjunct to pterygium surgery. 
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1.6 Literature review 
Hu et al. (2014) recently conducted a meta-analysis on randomised controlled trials using 
bevacizumab in treatment of pterygium. They concluded that topical or subconjunctival 
bevacizumab is relatively safe and well tolerated in the treatment of pterygium but has no 
statistically significant effect in pterygium recurrence. 
 
Appendix A presents the recent studies reporting on the use of ranibizumab on pterygium, 
while appendix B presents the recent studies reporting on the use of bevacizumab on 
pterygium. 
 
1.7 Rationale of the study 
To our knowledge, there have only been 3 published studies on the use of ranibizumab on 
pterygium (Galor et al., 2010; Hurmeric et al., 2013; Mandalos et al., 2010). However, none 
of the 3 studies address on the pterygium recurrence rate. This study addressed the gap in the 
literatures. The outcome will determine the potential use of ranibizumab as an adjunctive 
modality in pterygium surgery to preventing recurrence. The results will also serve as a 
platform for further study of ranibizumab uses in pterygium. 
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2 OBJECTIVES 
 
2.1 General objective 
To compare the pterygium vascularity and size before and after intralesional ranibizumab 
injection and the recurrence rate following sutureless pterygium surgery. 
 
2.2 Specific objectives 
1. To compare the vascularity of primary pterygium before and 1 week after 
intralesional ranibizumab (0.3 mg/0.03 mL) injection. 
 
2. To compare the size of primary pterygium before and 1 week after intralesional 
ranibizumab (0.3 mg/0.03 mL) injection. 
 
3. To compare the recurrence rate at 1 year after sutureless pterygium surgery between 
the group with and without intralesional ranibizumab injection. 
 
 
 
 
6 
 
3 METHODOLOGY 
 
3.1 Study design 
Prospective randomised controlled trial. 
 
3.2 Population, time and setting 
Study population 
All patients who attended eye clinic in HUSM and for primary pterygium excision. 
 
Study duration  
September 2012 - September 2014  
 
Study location 
Eye clinic, Hospital Universiti Sains Malaysia (HUSM) 
 
3.3 Sampling procedure 
Simple random sampling procedure was applied in this study. The study population who met 
with the inclusion and the exclusion criteria were labelled with a serial number. The study 
subjects were then selected randomly using a random digit table. 
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Based on the randomly selected numbers, the patients were then divided into two groups: 
 Treatment group (odd numbers): patients with intralesional ranibizumab 
 Control group (even numbers):  patients without intralesional ranibizumab 
 
3.4 Sample size 
Sample size calculation was done by using PS (Power and Sample Size) software. Power was 
set at 0.8 for each objective. 
 
Sample size calculation for objective 1 
Objective 1:  To compare the vascularity of primary pterygium before and 1 week after  
  intralesional ranibizumab (0.3 mg/0.03 mL) injection. 
Sample size was calculated based on paired t-test. The mean change in corneal 
vascularisation after 2 bevacizumab injections was -0.1% and standard deviation was 0.19 
(Bahar et al., 2008). 
 Design = paired t-test 
 Input: α = 0.05, power = 0.8, δ = 0.1, σ = 0.19 
 Sample size = 30  
 
Sample size calculation for objective 2 
Objective 2:  To compare the size of primary pterygium before and 1 week after 
intralesional ranibizumab (0.3 mg/0.03 mL) injection. 
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Sample size was calculated based on the mean difference in size of vascularised conjunctival 
bed before and after subconjunctival bevacizumab injection was 8.08 ± 5.5 % (Bayar et al., 
2014). 
 Design = paired t-test 
 Input: α = 0.05, power = 0.8, δ = 0.0808, σ = 0.055 
 Sample size = 6  
 
Sample size calculation for objective 3 
Objective 3:  To compare the recurrence rate at 1 year after sutureless pterygium surgery 
  between the group with and without intralesional ranibizumab injection   
Sample size was calculated based on no recurrence in the group treated with subconjunctival 
bevacizumab versus 9% recurrence rate in the control group (Ozgurhan et al., 2013). 
 Design = independent, prospective, two proportions, uncorrected Chi-square test 
Input: α = 0.05, power = 0.8, p0 = 0.09, p1 = 0.005 (estimated recurrence in treatment 
group), m = 1 
 Sample size = 97 per arm 
 
Due to the high cost of ranibizumab and our limited financial resources, it is not feasible to 
recruit such large sample size. Therefore, we were only able to recruited sample size of 18 
patients on each arm. With 18 subjects per arm, the post-hoc power for objective 1, 2 and 3 
are 55%, 100% and 22% respectively. 
For a pilot study, the sample size should be 10% of sample projected for the larger parent 
study (Connelly, 2008). 18 subjects per arm had met this criterion for all the 3 objectives. 
9 
 
Furthermore, for a study of medical filed, Julious (2005) and Van Belle (2011) suggested 12 
subjects. 
 
3.5 Selection criteria 
3.5.1 Inclusion criteria 
 All patients presenting with primary nasal pterygium who were indicated and agreed 
for pterygium excision surgery. 
 Grade T3 (fleshy) pterygium. 
3.5.2 Exclusion criteria 
 Patients with temporal or both nasal and temporal pterygium. 
 Patients with other ocular surface disorders. 
 Patients with glaucoma. 
 Previous ocular surgery or trauma. 
 History of systemic thromboembolic event. 
 Pregnant women and lactating mother. 
 
3.6 Protection of confidentiality 
To protect confidentiality of the patients, all photographs were assigned with a serial number. 
Data analysis was referred to the serial number. Photographs were kept under password 
protected storage by the main researcher.  
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3.7 Funding 
This research received no grant from any funding agency in the public, commercial or non-
profit sector. 
 
3.8 Ethical approval 
This study was approved by Human Research Ethics Committee of USM on 31
st
 July 2013 
[USM/JEPeM/269.3.(1)].  
 
This study adhered to the tenets of the Declaration of Helsinki. 
 
Informed consent was obtained from all patients after the nature and possible consequences 
of the study had been explained. All patient recruited were treated with intension to treat. 
Any care that requires urgent attention or referral was managed accordingly. 
 
3.9 Definition of terminologies 
3.9.1 Primary pterygium 
Primary pterygium was diagnosed clinically as fibrovascular growth from bulbar conjunctival 
extending beyond the limbus onto the cornea. It had never been excised previously. Clinical 
diagnosis was later confirmed with histological examination of the excised tissue. 
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Pterygium was graded according to simple grading system by Tan et al. (1997a). 
Grade T1: Atophic pterygium, episcleral vessels unobscured and the least likely to recur. 
Grade T2: Intermediate pterygium with episcleral vessels partially obscured.  
Grade T3: Fleshy pterygium, episcleral vessels totally obscured and the most likely to recur. 
 
Only grade T3 nasal pterygium was selected for this study. 
 
3.9.2 Ranibizumab  
Ranibizumab (Lucentis, Genetech.Inc) is a recombinant humanized IgG1 kappa isotype 
monoclonal antibody fragment produced in Escherichia coli cells by recombinant DNA 
technology.  
 
It is designed for intraocular used in wet age-related macular degeneration, macular oedema 
following retinal vein occlusion and diabetic macular oedema. 
 
It acts by binding to receptor binding site of active forms of VEGF-A, including the 
biologically active, cleaved form of this molecules, VEGF100. 
 
Its use in pterygium is off-labelled and there is no census on the correct dosage for its 
injection. Dosage of 0.3 mg/0.03 mL was used in this study. 
 
No previous documentation of half-life of ranibuzumab in pterygium was found. 
12 
 
3.9.3 Job location 
Job location was divided into outdoor and indoor. Outdoor job location was defined as 4 
hours or more per day during daylight of outdoor job activity. 
 
3.9.4 Corneal pterygium area  
Corneal pterygium area is defined as the percentage of pixels occupied by the pterygium 
within the cornea (Enkvetchakul et al., 2011). Aim is to quantify the pterygium size as a 
mean to monitoring regression post-ranibizumab injection. The final results were derived 
from the average results from the both principle researcher (Dr. Ho Hao Chi) who was not 
masked and co-supervisor (Dr. Khairy Shamel Sonny Teo) who was masked of the treatment 
choice.  
 
      Pterygium surface area (in pixels) 
Percentage of corneal pterygium area = -------------------------------------------- x 100% 
      Cornea surface area (in pixels) 
 
3.9.5 Pterygium vessel area  
Pterygium vessel area is defined as the percentage of pixels occupied by the vessels within 
the pterygium (Mandalos et al., 2010). Aim is to quantify the pterygium vascularity as a 
mean to monitor vessels regression post-ranibizumab injection. The final results were derived 
from the average results from both the principle researcher who was not masked and the co-
supervisor who was masked of the treatment choice.  
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      Pterygium surface area covered  
by vessels (in pixels) 
Percentage of pterygium vessels area = -------------------------------------------- x 100% 
      Pterygium surface area (in pixels) 
 
3.9.6 Recurrent pterygium 
Recurrence was observed clinically after 1 year from pterygium excision surgery.    
 
Grading of recurrent pterygium by Prabhasawat et al. (1997): 
Grade 1: Normal appearance of operative site. 
Grade 2:  Some fine episcleral vessels, but without any fibrous tissue in the excised  
  area extending up to but not beyond the limbus. 
Grade 3:  Presence of additional fibrous tissues in the excised area without invading the 
  cornea. 
Grade 4:  True recurrence with a fibrovascular tissue invading the cornea. 
 
Recurrence in our study is defined as true recurrence or grade 4 lesion. Recurrence was 
confirmed with agreement by both the principle researcher who was not masked and the 
supervisor (Assoc. Prof. Dr Mohtar Ibrahim) who was masked of the treatment  
 
3.10 Study procedure 
3.10.1 Subjects  
All patients attended Ophthalmology Clinic, Hospital Universiti Sains Malaysia from 
September, 2012 to September, 2014 who fulfilled the selection criteria were offered to 
participate in this study. Only those who gave written informed consent were recruited. They 
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were then randomised and divided into 2 groups, the treatment group and the control group. 
The treatment group received intralesional ranibizumab injection and the control group which 
did not receive ranibizumab injection.  Patients were not masked of their treatment choices 
because those who did not received intralesional ranibizumab injection were not subjected to 
injection of placebo. 
 
3.10.2 Image acquisition 
Anterior segment photographs were taken using Kowa VX-10 fundus camera adapted with 
Nikon digital camera D70s. The patients’ eyes focused at primary position during image 
acquisition.  
 
For the treatment group, first anterior segment photographs were taken immediately before 
injection of intralesional ranibizumab. Second photographs were taken 1 week after the 
injection, and coinciding with immediately before pterygium excision surgery. Third 
photographs were taken 1 year after pterygium excision.  
 
For the control group, first anterior segment photographs were taken immediately before 
pterygium excision surgery. Second photographs were taken 1 year after pterygium excision.  
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3.10.3 Image analysis 
Bock et al. (2008) and Tatham et al. (2011) had shown that semiautomated threshold analysis 
of corneal vessels is more accurate and reproducible then manually outlining each corneal 
vessels. 
 
Most studies on pterygium and cornea vascularity used NIH (National Institutes of Health) 
image software, Image J (Bahar et al., 2008; Bayar et al., 2014; Fallah et al., 2010; Fallah 
Tafti et al., 2011). We used Image J 1.48v. It is available for free online download in 
rsb.info.nih.gov/nih-image/. It consist of a 6-step algorithm improvised from methods 
previously described: contrast enhancement, cornea and pterygium boundary estimation, grey 
value image, background subtraction, auto threshold, automatic calculation (Benayoun et al., 
2012; Bock et al., 2008; Enkvetchakul et al., 2011). 
 
1. Contrast enhancement 
Contrast enhancement was made to the image to sharpen image contrast making visible 
structure more distinguishable. It is done by clicking on “process” then, “enhance contrast”. 
“saturated pixels” value was set at 0.4 as per default. “normalize” and “equalize histogram” 
are not checked so as not to alter the pixel of the images. 
 
 
2. Cornea and pterygium boundary estimation 
Using contrast enhanced images, the corneal surface area was manually outlined by “oval 
selection” tool according to the innermost vessels of the limbal arcade (Bock et al., 2008). 
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The image was cropped by clicking on “edit” followed by “clear outside”.  The cornea with 
its background removed became the region of interest. 
 
The cropped images of cornea with its “oval selection” tool still present, click “analyse” then 
click “measure”. The number displayed under “area” is the cornea surface area in pixels. The 
number was then recorded. 
 
The pterygium border was drawn manually using “freehand selection” tool. Then, click 
“analyze” then click “measure”. The number displayed under “area” was recorded as the 
pterygium area in pixels. The number was recorded. The image of outlined pterygium was 
then cropped by clicking “edit”, then “clear outside”. 
 
3. Grey value image 
The contrast enhanced images that has yet to be cropped were converted to 8-bits grey value 
images by clicking “image”, then “type”, then “8-bit”. This marked the darkest and the 
lightest pixel into black and white relatively and other pixels linearly in between. Each pixel 
can have a value of 0 (black) to 255 (white). The vessels will stand out as being darker than 
their background. 
 
4. Background subtraction 
Using the grey value images, background filtering was done by clicking “process”, then 
“subtract background”. “Rolling ball radius” was set at 50.0 pixels and the “light 
background” option was ticked as per default. The outcome was an image that has 
background filtered to reduce false positive and false negative. 
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5. Auto threshold 
Thresholding of images were done to highlight vessels automatically. It was done on 8-bits 
greyscaled images which background had been lightened. Only greyscaled images can be 
thresholded. The algorithm to thresholding the images were to click on “image”, “adjust”, 
and then “auto threshold”. “Default” method was chosen. 
 
6. Automatic calculation  
To select the area of pterygium vessels, open both the cropped pterygium image and the 
thesholded images were opened. Then, “process” followed by “image calculator” were 
clicked. Both images were selected as “image 1” and “image 2”. The “operation: OR” were 
selected, then “OK” was clicked.  
 
Because structure in the grey value images cannot be selected automatically, the images were 
converted to RGB images again by clicking “image”, “type”, and “RGB color”.  
 
With the RGB coloured images, threshold visible vessels were selected automatically by first 
clicking on “image”, “adjust”, then “threshold”. Secondly, choose “threshold color: red”, then 
adjust the threshold bar until all the vessels turn colour from grey to red. Thirdly, “select” 
button was clicked followed by “analyze”, and finally “measure”. The number displayed 
under “area” is the pterygium vessel area in pixels. 
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Figure 3.1 Sequential image analysis. (A) Original anterior segment image. (B) Contrast 
enhanced image; (C) cornea limbus and pterygium outlined; (D) cornea with background 
removed; (E) pterygium with background removed; (F) 8-bits grey value image; (G) 
background subtracted image; (H) threshold image; (I) calculated image of cropped 
pterygium image and threshold image; (J) automated calculation of cornea, pterygium and 
pterygium surface vessels area in pixels.  
20 
 
3.10.4 Intralesional ranibizumab injection 
Patients who were under intralesional ranibizumab group were treated as follows.  
 
Patients’ eyes were anaesthetised with topical proparacaine 0.5%. The eyes were then clean, 
draped and speculum applied. Topical povidone 5% was then applied to the cul-de-sac for 3 
minutes and flushed away. Intralesional ranibizumab 0.3 mg/0.03 mL was then injected into 
the body of the pterygium along the limbus.  
 
Patients were allowed home with topical chloramphenicol 0.5% 6 hourly for 1 week. Patients 
were then scheduled for pterygium excision in 1 week. 
 
3.10.5 Surgical procedure 
The pterygium excision surgery was done under topical anaesthesia using proparacaine 0.5%. 
Topical phenylephrine 2.5% was also instilled to reduce conjunctival bleeding.   
 
Surgical area was then cleaned, draped and lid speculum inserted. Topical povidone 5% 
applied to the cul-de-sac for 3 minutes and then flushed away. Intralesional lignocaine 1% 
was injected into the body of pterygium.  
 
The pterygium was then excised from the apex to the base using Took knife and Wescott 
scissors. The demarcation line of the pterygium intended to be excised was crushed using 
artery forceps to reduce bleeding. Once the pterygium had been excised, residual 
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fibrovascular tissue was scrapped off using Took knife. Haemostasis was achieved by 
pressure applied to bleeding site using cotton tip bud. 
 
The bare sclera was then covered with free conjunctival autograft that was harvested from 
superior bulbar conjunctiva after carefully separating it from underlying Tenon capsule. Size 
of the graft overlaps the edges of defect by 1mm horizontally and vertically.  
 
Conjunctival graft was then placed onto the bare sclera with fibrin adhesive glue (Tisseel VH; 
Baxter Healthcare, Corp).  Care was taken to maintain proper orientation of limbus edge 
towards limbus.  
 
The excised pterygium from both groups was labelled and the specimens were transported to 
pathology laboratory in 10% normal buffered formalin for examination under light 
microscopy for histological assessment. 
 
3.10.6 Post-operative follow-up 
Patients of both groups received both topical chloramphenicol 0.5% and topical prednisolone 
forte 1% each 2 hourly for 1 week then tapered down to 6 hourly for 1 month, then the 
medications were taken off thereafter. 
 
Patients of both groups were followed-up for 1 year postoperatively. Anterior segment 
photographs were taken at 1 year postoperation. On follow-ups, patients were assessed for 
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recurrence and complications such as graft dehiscence, conjunctival cyst and tenon 
granuloma.  
 
3.11 Method to minimize errors 
Study subjects were randomised and selected according to inclusion and exclusion criteria. 
Image acquisition, ranibizumab injection and pterygium excision were carried out by the 
principle investigator. Image analysis was performed by 2 independent observers. 
 
3.12 Statistical analysis 
The acquired data was entered into data collection sheet and subsequent analysis performed 
using latest IBM SPSS Statistics version 22. A p-value of <0.05 was considered to be 
statistically significant.  
  
All numerical data was checked for normality by using Shapiro-Wilk test and histogram. 
Normally distributed data was analysed with parametric test. Independent t-test was used to 
compare numerical data between 2 groups of independent samples and paired sample t-test to 
compare numerical data pre and post-intervention of the same sample. Skewed data was 
analysed using non-parametric test (Mann-Whitney U).  
 
To compare categorical data between the 2 groups, Pearson Chi-square was used. Fisher’s 
Exact test was used when equal or more than 20% of the cells has expected frequency of less 
than 5. 
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4 RESULTS 
 
4.1 Demographic data 
Table 4.1 Demographic characteristics of patients between the treatment and control group. 
  
Treatment 
Group 
(n = 18) 
 
 
Control 
Group 
(n = 18) 
 
 
p value 
 
Age (year) 
Median (IQR) 
 
 
55.0 (22.3) 
 
 
57.5 (19.8) 
 
 
0.350* 
 
Age group, n (%) 
<55  
>55  
 
 
10 (55.6) 
8 (44.4) 
 
 
7 (38.9) 
11 (61.1) 
 
 
0.317
#
 
 
Sex, n (%) 
     Male  
     Female 
 
 
13 (72.2) 
5 (27.8) 
 
 
11 (61.1) 
7 (38.9) 
 
 
0.480
#
 
 
Race, n (%) 
     Malay  
     Chinese 
 
 
16 (88.9) 
2 (11.1) 
 
 
16 (88.9) 
2 (11.1) 
 
 
> 0.950
##
 
 
Job location, n (%) 
     Outdoor 
     Indoor 
 
 
6 (33.3) 
12 (66.7) 
 
 
6 (33.3) 
12 (66.7) 
 
 
> 0.950
#
 
    
* Mann-Whitney U 
#
 Pearson Chi-square test 
##
 Fisher’s Exact Test 
IQR = interquartile range 
p value < 0.05 is considered significant  
 
This study was conducted on 36 eyes of 36 patients, 18 on each group. There was no 
statistically significant difference between the groups in term of age, age group, sex, race and 
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job location (p = 0.350, 0.317, 0.480, > 0.950 and > 0.950 respectively).  Mann-Whitney U, 
Chi-square and Fisher’s exact test were used to analyse the numerical and categorical data. 
 
The median age of patients in this study was 57.00 years with interquartile range of 23.50. 
Their age ranged from 40 to 77-year-old.  
 
4.2 Pterygium vessel area and corneal pterygium area before 
and after intralesional ranibizumab injection 
Table 4.2 Comparing pterygium vessel area and corneal pterygium area before and 1 week 
after intralesional ranibizumab injection in the treatment group. 
  
Before 
 
 
After 
 
Difference 
 
p value 
 
Pterygium vessel area (%) 
Mean (SD) 
 
 
 
 
15.33 (  4.92) 
 
 
13.85 (  5.79) 
 
 
1.48 (4.65) 
 
 
0.195* 
Corneal pterygium area (%) 
Mean (SD) 
 
 
 
17.39 (14.16) 
 
17.12 (13.61) 
 
0.28 (2.71) 
 
0.672* 
* Paired sample t-test 
SD = standard deviation 
p value < 0.05 is considered significant  
 
The mean pterygium vessel area before and after ranibizumab injection were 15.33 + 4.92% 
and 13.85 + 5.79%, respectively The reduction in pterygium vessel area after ranibizumab 
injection was 1.48 + 4.65%. The difference was statistically insignificant (p = 0.195).   
 
